RSLS vs. BIAF, ABT, ISRG, BSX, SYK, MDT, BDX, EW, IDXX, and RMD
Should you be buying ReShape Lifesciences stock or one of its competitors? The main competitors of ReShape Lifesciences include bioAffinity Technologies (BIAF), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Boston Scientific (BSX), Stryker (SYK), Medtronic (MDT), Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), and ResMed (RMD). These companies are all part of the "medical" sector.
ReShape Lifesciences vs. Its Competitors
bioAffinity Technologies (NASDAQ:BIAF) and ReShape Lifesciences (NASDAQ:RSLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.
In the previous week, ReShape Lifesciences had 7 more articles in the media than bioAffinity Technologies. MarketBeat recorded 10 mentions for ReShape Lifesciences and 3 mentions for bioAffinity Technologies. ReShape Lifesciences' average media sentiment score of 0.32 beat bioAffinity Technologies' score of -0.25 indicating that ReShape Lifesciences is being referred to more favorably in the news media.
bioAffinity Technologies has a beta of 2.52, indicating that its share price is 152% more volatile than the S&P 500. Comparatively, ReShape Lifesciences has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.
ReShape Lifesciences has a net margin of -48.26% compared to bioAffinity Technologies' net margin of -110.53%. ReShape Lifesciences' return on equity of -251.90% beat bioAffinity Technologies' return on equity.
1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 22.1% of ReShape Lifesciences shares are held by institutional investors. 16.9% of bioAffinity Technologies shares are held by company insiders. Comparatively, 0.0% of ReShape Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
bioAffinity Technologies presently has a consensus price target of $6.00, suggesting a potential upside of 2,177.04%. Given bioAffinity Technologies' higher possible upside, research analysts clearly believe bioAffinity Technologies is more favorable than ReShape Lifesciences.
ReShape Lifesciences has lower revenue, but higher earnings than bioAffinity Technologies. bioAffinity Technologies is trading at a lower price-to-earnings ratio than ReShape Lifesciences, indicating that it is currently the more affordable of the two stocks.
Summary
ReShape Lifesciences beats bioAffinity Technologies on 8 of the 14 factors compared between the two stocks.
Get ReShape Lifesciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RSLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
ReShape Lifesciences Competitors List
Related Companies and Tools
This page (NASDAQ:RSLS) was last updated on 7/2/2025 by MarketBeat.com Staff